BR112023020538A2 - Derivados heterocíclicos, composições farmacêuticas e seus usos no tratamento ou na melhoria de câncer - Google Patents
Derivados heterocíclicos, composições farmacêuticas e seus usos no tratamento ou na melhoria de câncerInfo
- Publication number
- BR112023020538A2 BR112023020538A2 BR112023020538A BR112023020538A BR112023020538A2 BR 112023020538 A2 BR112023020538 A2 BR 112023020538A2 BR 112023020538 A BR112023020538 A BR 112023020538A BR 112023020538 A BR112023020538 A BR 112023020538A BR 112023020538 A2 BR112023020538 A2 BR 112023020538A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical compositions
- cancer
- compounds
- improvement
- treatment
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000012453 solvate Substances 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
derivados heterocíclicos, composições farmacêuticas e seus usos no tratamento ou na melhoria de câncer. a presente invenção refere-se a compostos da fórmula (i) ou sais, solvatos, cocristais, tautômeros ou misturas dos mesmos. ademais, a presente invenção se refere a composições farmacêuticas que compreendem os ditos compostos. além disso, a presente invenção se refere aos compostos da fórmula (i) ou aos sais, aos solvatos, aos cocristais, aos tautômeros ou às misturas dos mesmos ou às composições farmacêuticas para uso como um medicamento e aos compostos da fórmula (i) ou aos sais, solvatos, cocristais, tautômeros ou misturas dos mesmos ou às composições farmacêuticas para uso no tratamento ou na melhoria de câncer. opcionalmente, os compostos da fórmula (i) ou os sais, os solvatos, os cocristais, os tautômeros ou as misturas dos mesmos ou as composições farmacêuticas são administrados em combinação com um segundo agente terapêutico, em particular, um agente anticâncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21167278 | 2021-04-07 | ||
PCT/EP2022/059295 WO2022214606A1 (en) | 2021-04-07 | 2022-04-07 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023020538A2 true BR112023020538A2 (pt) | 2024-01-23 |
Family
ID=75426525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023020538A BR112023020538A2 (pt) | 2021-04-07 | 2022-04-07 | Derivados heterocíclicos, composições farmacêuticas e seus usos no tratamento ou na melhoria de câncer |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP4320109A1 (pt) |
JP (1) | JP2024515061A (pt) |
KR (1) | KR20230167092A (pt) |
CN (1) | CN117355512A (pt) |
AR (1) | AR125312A1 (pt) |
AU (1) | AU2022253869A1 (pt) |
BR (1) | BR112023020538A2 (pt) |
CA (1) | CA3212085A1 (pt) |
IL (1) | IL307402A (pt) |
TW (1) | TW202304882A (pt) |
WO (1) | WO2022214606A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3714069A1 (en) * | 2017-11-20 | 2020-09-30 | Tolremo Therapeutics AG | Diagnostic method |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
ATE59966T1 (de) | 1983-09-26 | 1991-02-15 | Ehrenfeld Udo | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
AU756693B2 (en) | 1997-09-29 | 2003-01-23 | Novartis Ag | Stabilized bioactive preparations and methods of use |
EP1034826A1 (en) | 1999-03-05 | 2000-09-13 | Reuter Chemische Apparatebau | Co-crystallization process |
WO2001085136A2 (en) | 2000-05-10 | 2001-11-15 | Alliance Pharmaceutical Corporation | Phospholipid-based powders for drug delivery |
EP1458360B1 (en) | 2001-12-19 | 2011-05-11 | Novartis AG | Pulmonary delivery of aminoglycosides |
JP4616237B2 (ja) | 2006-11-07 | 2011-01-19 | 日本電信電話株式会社 | シリコン化合物薄膜の形成方法 |
IT201700047189A1 (it) * | 2017-05-02 | 2018-11-02 | Fondazione St Italiano Tecnologia | Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie |
WO2021064142A1 (en) * | 2019-10-02 | 2021-04-08 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer |
JP2022553859A (ja) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | Ras阻害剤 |
-
2022
- 2022-04-07 JP JP2023561897A patent/JP2024515061A/ja active Pending
- 2022-04-07 AR ARP220100874A patent/AR125312A1/es unknown
- 2022-04-07 TW TW111113263A patent/TW202304882A/zh unknown
- 2022-04-07 CN CN202280026783.3A patent/CN117355512A/zh active Pending
- 2022-04-07 CA CA3212085A patent/CA3212085A1/en active Pending
- 2022-04-07 EP EP22721083.8A patent/EP4320109A1/en active Pending
- 2022-04-07 BR BR112023020538A patent/BR112023020538A2/pt unknown
- 2022-04-07 IL IL307402A patent/IL307402A/en unknown
- 2022-04-07 AU AU2022253869A patent/AU2022253869A1/en active Pending
- 2022-04-07 WO PCT/EP2022/059295 patent/WO2022214606A1/en active Application Filing
- 2022-04-07 KR KR1020237038144A patent/KR20230167092A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
TW202304882A (zh) | 2023-02-01 |
AR125312A1 (es) | 2023-07-05 |
AU2022253869A1 (en) | 2023-10-05 |
IL307402A (en) | 2023-12-01 |
JP2024515061A (ja) | 2024-04-04 |
KR20230167092A (ko) | 2023-12-07 |
EP4320109A1 (en) | 2024-02-14 |
CA3212085A1 (en) | 2022-10-13 |
CN117355512A (zh) | 2024-01-05 |
WO2022214606A1 (en) | 2022-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021023825A2 (pt) | Inibidores heterobicíclicos de mat2a e métodos de uso para tratamento de câncer | |
BR112012030177A2 (pt) | composto, uso do mesmo, e, composição farmacêutica | |
DOP2022000266A (es) | 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
SV2010003491A (es) | 2- anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
BR112015028538A2 (pt) | derivados de sulfamoiltiofenamida e o uso dos mesmos como medicamentos para o tratamento da hepatite b | |
BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
BR112017010551A2 (pt) | composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento. | |
BR112015021549A2 (pt) | inibidores de piridina cinase cdk9 | |
BR112023024646A2 (pt) | Composto tetacíclico fundido, método de preparação do mesmo e aplicação do mesmo na medicina | |
BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
BR112022008000A2 (pt) | Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo | |
BR112015022758A2 (pt) | derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia | |
BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
BR112022000251A2 (pt) | Derivados macrocíclicos de espirociclo como inibidores de mcl-1 | |
BR112022001567A2 (pt) | Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias. | |
BR112023000212A2 (pt) | Éter macrocíclico contendo derivados de indol como inibidores de mcl-1 | |
BR112022021748A2 (pt) | Compostos e composições para inibir a atividade de hif2a e seus métodos de uso | |
BR112023020538A2 (pt) | Derivados heterocíclicos, composições farmacêuticas e seus usos no tratamento ou na melhoria de câncer | |
BR112019007863A2 (pt) | derivados de naftiridinona inovadores e seu uso no tratamento de arritmia | |
BR112021017957A2 (pt) | Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo | |
BR112015031846A8 (pt) | derivados de estratrientiazol, seus usos, e composição farmacêutica | |
BR112022025028A2 (pt) | Moduladores de molécula pequena de il-17 | |
BR112023015913A2 (pt) | Compostos novos |